UK markets closed

BioPorto A/S (BIOPOR.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
2.2250+0.1100 (+5.20%)
At close: 04:59PM CEST
Full screen
Previous close2.1150
Open2.1700
Bid2.2200 x 0
Ask2.2250 x 0
Day's range2.1050 - 2.2600
52-week range1.1800 - 3.8500
Volume2,688,676
Avg. volume1,005,766
Market cap955.987M
Beta (5Y monthly)1.21
PE ratio (TTM)N/A
EPS (TTM)-0.1500
Earnings date15 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury

    July 11, 2024 News Release Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury COPENHAGEN, Denmark and BOSTON, MA, USA, July 11, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), received marketing clearance by the US Food and Drug Administration (FDA) for ProNephro AKI™ (NGAL) for r

  • GlobeNewswire

    Grant of Warrants

    4 July 2024Announcement no. 17 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, July 4, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the annual general meeting’s resolution on April 30, 2024, to issue a total of 6,000,000 warrants to a new member of the executive leadership team. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 2.14 per

  • GlobeNewswire

    BioPorto confirms market acceptance of NGAL products with US standing order.

    July 1, 2024 News Release BioPorto confirms market acceptance of NGAL products with US standing order. COPENHAGEN, Denmark and BOSTON, MA, USA, July 1, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that it has received its first standing order for its NGAL (“neutrophil gelatinase-associated lipocalin”) assays for clinical chemistry platforms. The or